Regeneron License and Collaboration Arrangement - Additional Information (Details) - USD ($)				3 Months Ended			12 Months Ended
	Jan. 28, 2022	Jul. 31, 2019	Jul. 29, 2016	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2020	Dec. 31, 2018	Dec. 31, 2017
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contract Assets				$ 0
Licence agreement cumulative revenue recognised					$ 27,000.0
Regeneron Pharmaceuticals, Inc.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Exercise Fee Paid	$ 20,000,000.0
Contingent Consideration fees			$ 20,000,000.0
Option exercise fee				20,000,000
Agreement transaction price			55,000,000.0
Licence agreement additional revenue recognised				25,000,000.0
Research funding fee			30,000,000.0
Non refundable upfront payment received				25,000,000.0
Additional payment for research funding received			$ 30,000,000.0	$ 20,000,000.0			$ 5,000,000.0	$ 5,000,000.0
License agreement termination description				twelve years
Contract research term period			5 years
Upfront payment			$ 25,000,000.0		25,000,000.0
Licence agreement cumulative revenue recognised						$ 10,000,000.0
Increase in estimated transaction price		$ 35,000,000.0
Contract liability				$ 0	$ 18,000,000.0
Regeneron Pharmaceuticals, Inc. | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Licence agreement additional amount payable of option exercise fees				$ 100,000,000.0
Increase in estimated transaction price						45,000,000.0
Regeneron Pharmaceuticals, Inc. | Minimum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Increase in estimated transaction price						$ 10,000,000.0